47.66
price up icon1.88%   0.88
pre-market  プレマーケット:  48.08   0.42   +0.88%
loading
前日終値:
$46.78
開ける:
$47.47
24時間の取引高:
2.12M
Relative Volume:
0.98
時価総額:
$3.71B
収益:
$170.10M
当期純損益:
$-239.59M
株価収益率:
-17.02
EPS:
-2.8
ネットキャッシュフロー:
$-191.20M
1週間 パフォーマンス:
+7.27%
1か月 パフォーマンス:
+29.30%
6か月 パフォーマンス:
+16.41%
1年 パフォーマンス:
-14.82%
1日の値動き範囲:
Value
$46.85
$48.48
1週間の範囲:
Value
$43.23
$48.48
52週間の値動き範囲:
Value
$30.04
$63.68

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name
名前
Crispr Therapeutics Ag
Name
セクター
Healthcare (1170)
Name
電話
(617) 315-4600
Name
住所
BAARERSTRASSE 14, ZUG
Name
職員
393
Name
Twitter
@crisprtx
Name
次回の収益日
2024-12-05
Name
最新のSEC提出書
Name
CRSP's Discussions on Twitter

CRSP を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CRSP
Crispr Therapeutics Ag
47.66 3.71B 170.10M -239.59M -191.20M -2.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.82 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
520.29 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.94 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.53 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
267.12 28.51B 3.81B -644.79M -669.77M -6.24

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-14 アップグレード Evercore ISI In-line → Outperform
2025-02-12 アップグレード TD Cowen Sell → Hold
2025-02-03 開始されました H.C. Wainwright Buy
2024-08-06 繰り返されました Needham Buy
2024-08-02 開始されました Rodman & Renshaw Buy
2024-06-28 再開されました Guggenheim Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-12-11 ダウングレード TD Cowen Market Perform → Underperform
2023-10-17 ダウングレード Cantor Fitzgerald Overweight → Neutral
2023-09-27 開始されました Mizuho Buy
2023-08-17 アップグレード Citigroup Neutral → Buy
2023-05-30 開始されました William Blair Outperform
2023-04-13 開始されました Cantor Fitzgerald Overweight
2023-03-21 開始されました Bernstein Mkt Perform
2023-03-17 開始されました Bryan Garnier Buy
2023-03-07 開始されました Robert W. Baird Neutral
2022-10-11 開始されました Morgan Stanley Underweight
2022-08-09 ダウングレード Barclays Overweight → Equal Weight
2022-06-23 ダウングレード Evercore ISI Outperform → In-line
2022-06-17 開始されました BMO Capital Markets Outperform
2022-04-28 開始されました Credit Suisse Neutral
2021-12-07 開始されました Cowen Market Perform
2021-10-19 開始されました SVB Leerink Outperform
2021-06-14 アップグレード Citigroup Sell → Neutral
2021-04-21 アップグレード Jefferies Hold → Buy
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-10 繰り返されました Chardan Capital Markets Buy
2020-12-10 ダウングレード Jefferies Buy → Hold
2020-12-10 繰り返されました Needham Buy
2020-12-07 ダウングレード Wells Fargo Overweight → Equal Weight
2020-10-23 開始されました RBC Capital Mkts Sector Perform
2020-10-05 開始されました BofA Securities Buy
2020-07-28 繰り返されました Needham Buy
2020-07-14 開始されました SunTrust Buy
2020-06-15 繰り返されました Canaccord Genuity Buy
2020-03-05 開始されました Stifel Hold
2020-02-03 ダウングレード Evercore ISI Outperform → In-line
2019-11-19 アップグレード William Blair Mkt Perform → Outperform
2019-11-12 アップグレード Oppenheimer Perform → Outperform
2019-08-01 開始されました Jefferies Buy
2019-07-26 開始されました Canaccord Genuity Buy
2019-06-10 開始されました ROTH Capital Buy
2019-04-12 開始されました Evercore ISI Outperform
2019-03-14 開始されました William Blair Mkt Perform
2019-01-28 ダウングレード Goldman Buy → Neutral
2019-01-22 ダウングレード Citigroup Neutral → Sell
すべてを表示

Crispr Therapeutics Ag (CRSP) 最新ニュース

pulisher
Jun 18, 2025

CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Traders Buy High Volume of Call Options on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

From Now to 2032: Unpacking the Genome Editing Market's - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

CRISPR Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - Yahoo

Jun 18, 2025
pulisher
Jun 18, 2025

Citizens JMP reiterates CRISPR Therapeutics stock rating on in-vivo progress - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

SG Americas Securities LLC Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Jun 18, 2025
pulisher
Jun 17, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpShould You Buy? - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025
pulisher
Jun 16, 2025

25,341 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Avanza Fonder AB - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million? - 24/7 Wall St.

Jun 15, 2025
pulisher
Jun 14, 2025

Millennium Management LLC Trims Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Equities Analysts Set Expectations for CRSP FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Crispr extends gains for the seventh consecutive trading day - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Crispr Therapeutics: Betting On A One-Shot Future (NASDAQ:CRSP) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Trend Tracker for (CRSP) - news.stocktradersdaily.com

Jun 13, 2025
pulisher
Jun 13, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 6%Here's What Happened - MarketBeat

Jun 13, 2025
pulisher
Jun 13, 2025

Crispr Therapeutics AG: Stock Soars Amid Bullish Trends - MSN

Jun 13, 2025
pulisher
Jun 11, 2025

CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Crispr Therapeutics: Early-Stage Research Updates Show Promise (NASDAQ:CRSP) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Weighs in on CRSP FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts - Yahoo Finance

Jun 10, 2025
pulisher
Jun 10, 2025

Crispr Therapeutics (CRSP) Rallies Amid FDA Fast-Tracking News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Crispr extends gains for the seventh consecutive trading day (CRSP:NASDAQ) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 09, 2025

CRISPR Therapeutics AG shareholders approve key proposals By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

CRISPR Therapeutics AG Shareholders Approve Key Proposals - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

CRISPR Therapeutics AG shareholders approve key proposals - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Wealth Enhancement Advisory Services LLC Has $1.08 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - MSN

Jun 08, 2025
pulisher
Jun 07, 2025

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month - simplywall.st

Jun 07, 2025
pulisher
Jun 05, 2025

Crispr: Shares Very Undervalued, as Early-Stage Pipeline Makes Progress and Casgevy Launch Underway - Morningstar

Jun 05, 2025
pulisher
Jun 05, 2025

CRSP Sees Significant Increase in Bullish Option Activity | CRSP Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Crispr Therapeutics call volume above normal and directionally bullish - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Raised by Green Alpha Advisors LLC - MarketBeat

Jun 05, 2025
pulisher
Jun 04, 2025

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - sharewise

Jun 04, 2025
pulisher
Jun 03, 2025

Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Can CRISPR Build On Casgevy's Success With Its In Vivo Pipeline? - Barchart.com

Jun 03, 2025
pulisher
Jun 03, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Voloridge Investment Management LLC - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

Capital Market Strategies LLC Buys 9,652 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

Q2 EPS Forecast for CRISPR Therapeutics Increased by Analyst - MarketBeat

Jun 03, 2025

Crispr Therapeutics Ag (CRSP) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Crispr Therapeutics Ag (CRSP) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Kulkarni Samarth
Chief Executive Officer
Mar 21 '25
Sale
41.23
10,031
413,578
195,085
Bruno Julianne
Chief Operating Officer
Mar 21 '25
Sale
41.23
1,714
70,668
10,544
Prasad Raju
Chief Financial Officer
Mar 21 '25
Sale
41.23
2,197
90,582
16,767
KASINGER JAMES R.
General Counsel and Secretary
Mar 21 '25
Sale
41.23
3,185
131,318
81,729
Prasad Raju
Chief Financial Officer
Mar 17 '25
Sale
41.80
3,762
157,252
12,714
Kulkarni Samarth
Chief Executive Officer
Mar 11 '25
Sale
42.42
9,973
423,055
180,890
Kulkarni Samarth
Chief Executive Officer
Mar 12 '25
Sale
43.32
4,462
193,294
185,428
KASINGER JAMES R.
General Counsel and Secretary
Mar 11 '25
Sale
42.42
2,850
120,897
77,530
KASINGER JAMES R.
General Counsel and Secretary
Mar 12 '25
Sale
43.32
1,116
48,345
78,664
Bruno Julianne
Chief Operating Officer
Mar 11 '25
Sale
42.42
1,198
50,819
8,263
$20.52
price down icon 1.06%
$35.91
price down icon 0.64%
$21.27
price up icon 1.67%
$104.85
price down icon 0.99%
$104.80
price down icon 0.28%
biotechnology ONC
$267.12
price up icon 0.12%
大文字化:     |  ボリューム (24 時間):